Rancho Santa Margarita, Calif. and Bedford, Mass. (July 14, 2020) — Blue California, a science-based, innovative ingredient solution provider, has just filed for a patent on therapeutic uses of the ingredient Ergothioneine. This follows Blue California’s Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress. Specifically, it claims that Ergothioneine can mitigate oxidative stress triggering the inflammatory response in many chronic conditions associated with heart disease, diabetes and cancer. Also, in support of other oxidative conditions associated with oxidative stress including COVID-19 as well as other viral diseases…
...Blue California is one of the only companies in the United States that has received a no-objection from the FDA to its GRAS notification on Ergothioneine with their branded ingredient ErgoActive [exclusively manufactured and distributed for] Conagen, a greater Boston area biotechnology company with a large portfolio of products for the food, nutrition, and pharma markets...
Press release from Blue California (more at the link) via FoodDive.com (a free site — more at the link), wikipedia & google links added.
Seems like a pretty sweeping assertion of effectivity. I would guess that the patent filing is geared more to protect the proprietary research process than to suggest any readiness of products for use in healthcare. Knowledgeable commenters likely can offer more information.